1/31
10:17 pm
aclx
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
Low
Report
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
1/30
12:53 am
aclx
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
Low
Report
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
1/23
05:06 am
aclx
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
04:14 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
1/21
04:00 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
1/7
10:02 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/7
04:06 am
aclx
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
Medium
Report
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
12/24
07:01 pm
aclx
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
12/24
06:15 am
aclx
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
Low
Report
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
12/22
05:01 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
12/17
08:24 am
aclx
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
Low
Report
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
12/8
01:20 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
12/8
08:07 am
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
12/6
02:24 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]
Medium
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]
12/6
02:24 pm
aclx
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
Medium
Report
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
12/6
02:00 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Medium
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
11/30
05:51 am
aclx
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
Medium
Report
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/18
04:13 pm
aclx
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]
Low
Report
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]
11/18
04:00 pm
aclx
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
Low
Report
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
11/18
09:00 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/7
03:36 pm
aclx
How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses [Yahoo! Finance]
Low
Report
How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses [Yahoo! Finance]
11/5
04:00 pm
aclx
Arcellx Provides Third Quarter 2025 Financial Results
Low
Report
Arcellx Provides Third Quarter 2025 Financial Results